- The condition, NASH, short for
- Madrigal showed in a phase 2 study with 73 patients that its treatment was better than placebo at reducing fat in the liver, and the treatment managed to resolve NASH in 27% of the patients who received treatment, compared to just 6% of those in the placebo group.
- Madrigal's stock was up 60% before markets opened on Thursday on the results.
ADVERTISEMENT
Drugmaker Madrigal just came out with some promising data for its treatment of NASH, a 'silent disease' millions are living with — and the stock is exploding
Madrigal showed in a phase 2 study with 73 patients that its treatment was better than placebo at reducing fat in the liver, and the treatment managed to resolve NASH in 27% of the patients who received treatment, compared to just 6% of those in the placebo group.
ADVERTISEMENT
Recommended articles
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT